Treatment-emergent adverse events grouped by safety topics of interest – second overall survival interim analysis. Credit: Ken Herrmann, Oliver Sartor, et al. New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the PSMAfore study underscore the statistically significant and clinically meaningful radiographic progression-free survival (rPFS) benefit of [177Lu]Lu-PSMA-617 radioligand therapy for patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). This study was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting and was honored as the Read More